Drugs /

anti-cd3/cd38 bispecific monoclonal antibody amg 424

Back to Drugs List

Overview

NCI Definition [1]:
A humanized, bispecific monoclonal antibody (BsAb) targeting CD3, a T-cell surface antigen, and CD38, a human cell surface glycoprotein and tumor-associated antigen (TAA), with potential antineoplastic activity. Upon intravenous administration, anti-CD3/CD38 bispecific monoclonal antibody AMG 424 binds to both CD3 on T-cells and CD38 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.

Clinical Trials

View Clinical Trials for anti-cd3/cd38 bispecific monoclonal antibody amg 424

Anti-cd3/cd38 bispecific monoclonal antibody amg 424 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating anti-cd3/cd38 bispecific monoclonal antibody amg 424, 1 is phase 1 (0 open).

Multiple myeloma is the most common disease being investigated in anti-cd3/cd38 bispecific monoclonal antibody amg 424 clinical trials [2].

Drug Details

Synonyms [2]:
amg424, amg-424, amg 424, cd3xcd38 bsab amg 424, anti-cd3/cd38 bispecific monoclonal antibody amg 424, anti-cd3/anti-cd38 bispecific monoclonal antibody amg 424, anti-cd3 x anti-cd38 bispecific monoclonal antibody amg 424
Drug Target(s) [2]:
CD3, CD38
NCIT ID [1]:
C153147

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.